Intra-Cellular Therapies, Inc. Quarterly Liabilities and Equity in USD from Q4 2012 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.
Summary
Intra-Cellular Therapies, Inc. quarterly Liabilities and Equity history and growth rate from Q4 2012 to Q2 2024.
  • Intra-Cellular Therapies, Inc. Liabilities and Equity for the quarter ending June 30, 2024 was $1.32B, a 85% increase year-over-year.
Liabilities and Equity, Quarterly (USD)
Liabilities and Equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q2 2024 $1.32B +$607M +85% Jun 30, 2024 10-Q 2024-08-07
Q1 2024 $747M +$24.9M +3.45% Mar 31, 2024 10-Q 2024-05-07
Q4 2023 $728M -$26.5M -3.51% Dec 31, 2023 10-Q 2024-08-07
Q3 2023 $718M -$64.3M -8.23% Sep 30, 2023 10-Q 2023-11-02
Q2 2023 $714M -$98.3M -12.1% Jun 30, 2023 10-Q 2023-08-03
Q1 2023 $722M -$146M -16.9% Mar 31, 2023 10-Q 2023-05-04
Q4 2022 $755M +$265M +54.1% Dec 31, 2022 10-K 2024-02-22
Q3 2022 $782M +$225M +40.4% Sep 30, 2022 10-Q 2022-11-03
Q2 2022 $812M +$186M +29.8% Jun 30, 2022 10-Q 2022-08-09
Q1 2022 $869M +$194M +28.8% Mar 31, 2022 10-Q 2022-05-10
Q4 2021 $490M -$227M -31.7% Dec 31, 2021 10-K 2023-03-01
Q3 2021 $557M -$214M -27.8% Sep 30, 2021 10-Q 2021-11-09
Q2 2021 $626M +$185M +41.9% Jun 30, 2021 10-Q 2021-08-09
Q1 2021 $674M +$193M +40.2% Mar 31, 2021 10-Q 2021-05-10
Q4 2020 $717M +$466M +186% Dec 31, 2020 10-K 2022-03-01
Q3 2020 $771M +$491M +175% Sep 30, 2020 10-Q 2020-11-09
Q2 2020 $441M +$131M +42.3% Jun 30, 2020 10-Q 2020-08-10
Q1 2020 $481M +$138M +40.3% Mar 31, 2020 10-Q 2020-05-07
Q4 2019 $251M -$106M -29.7% Dec 31, 2019 10-K 2021-02-25
Q3 2019 $281M -$105M -27.2% Sep 30, 2019 10-Q 2019-11-05
Q2 2019 $310M -$102M -24.8% Jun 30, 2019 10-Q 2019-08-07
Q1 2019 $343M -$103M -23% Mar 31, 2019 10-Q 2019-05-08
Q4 2018 $357M -$114M -24.2% Dec 31, 2018 10-K 2020-03-02
Q3 2018 $386M +$51.4M +15.4% Sep 30, 2018 10-Q 2018-11-07
Q2 2018 $412M +$62.5M +17.9% Jun 30, 2018 10-Q 2018-08-02
Q1 2018 $446M +$73.3M +19.7% Mar 31, 2018 10-Q 2018-05-03
Q4 2017 $471M +$82.6M +21.2% Dec 31, 2017 10-K 2019-02-27
Q3 2017 $334M -$208M -38.4% Sep 30, 2017 10-Q 2017-11-08
Q2 2017 $350M -$98.1M -21.9% Jun 30, 2017 10-Q 2017-08-09
Q1 2017 $372M -$91.4M -19.7% Mar 31, 2017 10-Q 2017-05-10
Q4 2016 $389M -$95.2M -19.7% Dec 31, 2016 10-K 2018-03-01
Q3 2016 $543M +$29.4M +5.74% Sep 30, 2016 10-Q 2016-11-09
Q2 2016 $448M +$234M +110% Jun 30, 2016 10-Q 2016-08-04
Q1 2016 $464M +$227M +95.5% Mar 31, 2016 10-Q 2016-04-28
Q4 2015 $484M +$353M +269% Dec 31, 2015 10-K 2017-03-01
Q3 2015 $513M +$376M +273% Sep 30, 2015 10-Q 2015-11-05
Q2 2015 $213M +$72.1M +51% Jun 30, 2015 10-Q 2015-08-05
Q1 2015 $237M +$90.5M +61.7% Mar 31, 2015 10-Q 2015-04-30
Q4 2014 $131M +$92.7M +241% Dec 31, 2014 10-K 2016-02-25
Q3 2014 $138M +$90.3M +191% Sep 30, 2014 10-Q 2014-11-03
Q2 2014 $141M +$141M Jun 30, 2014 10-Q 2014-08-12
Q1 2014 $147M +$147M Mar 31, 2014 10-Q 2014-05-05
Q4 2013 $38.4M +$18.6M +94% Dec 31, 2013 10-K 2015-03-12
Q3 2013 $47.3M Sep 30, 2013 10-Q 2013-11-05
Q2 2013 $49.00* Jun 30, 2013 10-Q 2013-08-15
Q1 2013 $4.07K* Mar 31, 2013 10-Q 2013-08-15
Q4 2012 $19.8M Dec 31, 2012 10-K 2014-03-25
* An asterisk sign (*) next to the value indicates that the value is likely invalid.